CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL
BACKGROUND: A second allogeneic transplant (HSCT2) may offer cure for selected patients with acute lymphoblastic leukemia (ALL) relapsing after first transplant (HSCT1), however, outcomes have historically been poor, largely driven by high incidence of subsequent relapse. Careful optimization of patient selection and timing of transplant remains critical to maximize long-term outcomes.
BACKGROUND: A second allogeneic transplant (HSCT2) may offer cure for selected patients with acute lymphoblastic leukemia (ALL) relapsing after first transplant (HSCT1), however, outcomes have historically been poor, largely driven by high incidence of subsequent relapse. Careful optimization of patient selection and timing of transplant remains critical to maximize long-term outcomes.
What the study was
- Study design
- Retrospective cohort study
- Population
- Patients
- Sample size
- 23
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and cellular therapy
Why it surfaced
Matched Hematologic malignancies, Novel therapeutics; Retrospective cohort study; human study; score 8/10 (n=3 r=3 dq=1 pop=1)
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.